A comparison of reweighting estimators of average treatment effects in real world populations

por Lin, Chen‐Yen, Kaizar, Eloise, Faries, Douglas, Johnston, Joseph
Publicado 2021

Electronegative Low-Density Lipoprotein L5 Impairs Viability and NGF-Induced Neuronal Differentiation of PC12 Cells via LOX-1

por Wang, Jiz-Yuh, Lai, Chiou-Lian, Lee, Ching-Tien, Lin, Chen-Yen
Publicado 2017

A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire

por Tillett, William, Lin, Chen-Yen, Zbrozek, Art, Sprabery, Aubrey Trevelin, Birt, Julie
Publicado 2019

Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors

por Kirkham, Bruce, Sesin, Carlos, Gellett, Amanda M., Sprabery, Aubrey T., Lin, Chen-Yen, Turkiewicz, Anthony
Publicado 2021

Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatme...

por Armstrong, April W., Foster, Shonda A., Comer, Brian S., Lin, Chen-Yen, Malatestinic, William, Burge, Russel, Goldblum, Orin
Publicado 2018

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis

por Gladman, Dafna, Nash, Peter, Goto, Hitoshi, Birt, Julie A, Lin, Chen-Yen, Orbai, Ana-Maria, Kvien, Tore K
Publicado 2020

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psori...

por Coates, Laura C, Kishimoto, Mitsumasa, Gottlieb, Alice, Shuler, Catherine L, Lin, Chen-Yen, Lee, Chin Hyok, Mease, Philip J
Publicado 2017

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST

por Braun, Jürgen, Kiltz, Uta, Deodhar, Atul, Tomita, Tetsuya, Dougados, Maxime, Bolce, Rebecca, Sandoval, David, Lin, Chen-Yen, Walsh, Jessica
Publicado 2022

Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis

por Bacci, Elizabeth D., DeLozier, Amy M., Lin, Chen-Yen, Gaich, Carol L., Rooney, Terence, Hoffman, Richard, Wyrwich, Kathleen W.
Publicado 2017

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies

por Kavanaugh, Arthur, Gottlieb, Alice, Morita, Akimichi, Merola, Joseph F, Lin, Chen-Yen, Birt, Julie, Shuler, Catherine L, Hufford, Matthew M, Thaçi, Diamant
Publicado 2019

Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies

por Combe, Bernard, Tsai, Tsen-Fang, Huffstutter, J. Eugene, Sprabery, Aubrey Trevelin, Lin, Chen-Yen, Park, So Young, Kronbergs, Andris, Hufford, Matthew M., Nash, Peter
Publicado 2021

Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis

por Bacci, Elizabeth D., DeLozier, Amy M., Lin, Chen-Yen, Gaich, Carol L., Zhang, Xiang, Rooney, Terence, de Bono, Stephanie, Hoffman, Richard, Wyrwich, Kathleen W.
Publicado 2017

Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1)

por Gottlieb, Alice B, Strand, Vibeke, Kishimoto, Mitsumasa, Mease, Philip, Thaçi, Diamant, Birt, Julie, Lee, Chin H, Shuler, Catherine L, Lin, Chen-Yen, Gladman, Dafna D
Publicado 2018

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab

por Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Malatestinic, William N, Lin, Chen-Yen, Lew, Carolyn R, Zimmerman, Nicole M, Goldblum, Orin M, Zhu, Baojin, Murage, Mwangi J
Publicado 2020

Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

por Kwon, Ohsang, Senna, Maryanne M., Sinclair, Rodney, Ito, Taisuke, Dutronc, Yves, Lin, Chen-Yen, Yu, Guanglei, Chiasserini, Chiara, McCollam, Jill, Wu, Wen-Shuo, King, Brett
Publicado 2023

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, doub...

por Mease, Philip J, van der Heijde, Désirée, Ritchlin, Christopher T, Okada, Masato, Cuchacovich, Raquel S, Shuler, Catherine L, Lin, Chen-Yen, Braun, Daniel K, Lee, Chin H, Gladman, Dafna D
Publicado 2017

Deciphering the evolution of composite-type GSKIP in mitochondria and Wnt signaling pathways

por Tsai, Cheng-Yu, Chiou, Shean-Jaw, Ko, Huey-Jiun, Cheng, Yu-Fan, Lin, Sin-Yi, Lai, Yun-Ling, Lin, Chen-Yen, Wang, Chihuei, Cheng, Jiin-Tsuey, Liu, Hsin-Fu, Kwan, Aij-Li, Loh, Joon-Khim, Hong, Yi-Ren
Publicado 2022

Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials

por Leonardi, Craig, Reich, Kristian, Foley, Peter, Torii, Hideshi, Gerdes, Sascha, Guenther, Lyn, Gooderham, Melinda, Ferris, Laura K., Griffiths, Christopher E. M., ElMaraghy, Hany, Crane, Heidi, Patel, Himanshu, Burge, Russel, Gallo, Gaia, Shrom, David, Leung, Ann, Lin, Chen-Yen, Papp, Kim
Publicado 2020

Thioridazine Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/β-Catenin Signaling Pathway in Glioma Cells

por Chu, Cheng-Wei, Ko, Huey-Jiun, Chou, Chia-Hua, Cheng, Tai-Shan, Cheng, Hui-Wen, Liang, Yu-Hsin, Lai, Yun-Ling, Lin, Chen-Yen, Wang, Chihuei, Loh, Joon-Khim, Cheng, Jiin-Tsuey, Chiou, Shean-Jaw, Su, Chun-Li, Huang, Chi-Ying F., Hong, Yi-Ren
Publicado 2019